Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)

计划入组 23 人 · 首次发布于 2025 年 2 月 21 日

Abo Follow-up Study

计划入组 1,600 人 · 首次发布于 2017 年 8 月 9 日

Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease

计划入组 5 人 · 首次发布于 2019 年 9 月 13 日

ABO-2203

ABO-2011

ABO-2202

Abo Holdings, Inc.

United States

Biglari Holdings

United States

BrightView Holdings

United States

GC Biopharma Expands U.S. Plasma Collection Network with FDA Approval of Calexico Facility

Repare Therapeutics' Gynecological Cancer Trial Shows Mixed Results, Beigene Inks $1.5B Deal for MAT2A Inhibitor

FDA Clears IND for Arbor Biotechnologies' ABO-101 Gene-Editing Therapy for Primary Hyperoxaluria Type 1